– Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate Vγ9Vδ2 (Gamma Delta) T Cells in the Presence of EGFR-Expressing Solid Tumors – – LAVA to Receive Upfront Payment of $50 Million, With Potential for Milestones of up to Approximately $650 Million and Royalties– – Seagen also has … [Read more…]

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction (the “Company” or “Anebulo”), today announced that it has agreed to sell an aggregate of 2,264,650 common shares and accompanying warrants to purchase up to 2,264,650 shares of common stock … [Read more…]

Lower doses of ANEB-001 reduced the negative effects of higher doses of THC Currently exploring delayed dosing to better understand real-world conditions AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction (the “Company” or “Anebulo”), today announced positive interim … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Biotechnology Market Research Report by Technology (Cell-based Assays, Chromatography, and DNA Sequencing), Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Biotechnology Market size was estimated at USD 876.74 billion in 2021, USD … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Epilepsy Monitoring Device Market Research Report by Product (Conventional Devices and Wearable Devices), End User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Epilepsy Monitoring Device Market size was estimated at USD 480.45 … [Read more…]

NEW YORK & MAINZ, Germany–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of … [Read more…]

New genes implicated in disease create new therapeutic targets and ability to assess disease severity. LOS ANGELES–(BUSINESS WIRE)–Retinoblastoma is a cancer of the eye that occurs in infants and toddlers and can lead to loss of vision, loss of one or both eyes, and even death. Unlike most tumors, these cannot be biopsied because of … [Read more…]

First patient dosed with ATA-100 gene replacement therapy for LGMD-R9 On-going multicenter, Phase 1/2 study evaluating safety, pharmacodynamic and efficacy of ATA-100 EVRY, France–(BUSINESS WIRE)–Atamyo Therapeutics, a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular diseases, today announced the dosing with ATA-100 of a first patient in a phase 1/2 clinical … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “4-Hour Virtual Seminar on FDA Trends for Computer System Validation (CSV) Compliance and Enforcement” webinar has been added to ResearchAndMarkets.com’s offering. Upon completion of this session, attendees will have an understanding of FDA compliance and enforcement as it relates to computer system validation. They will understand how to develop the most robust computer … [Read more…]

MUNICH, Germany–(BUSINESS WIRE)–CatalYm today announced that it has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration (FDA) to expand its ongoing Phase 2 clinical program to include clinical trial centers in the U.S. The ongoing GDFATHER-2 program (GDF-15-neutralizing antibody-mediated human effector cell relocation) is evaluating the company’s lead candidate, … [Read more…]